UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 82, 2009

APEX BIOVENTURES ACQUISITION CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	6770	20-4997725
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

18 Farm Lane

Hillsborough, California 94010

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 344-3029

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

~~Apex~~At a ~~Bioventures~~special ~~Acquisition~~meeting ~~Corp.~~of ~~(the~~stockholders ~~“Company”)~~held ~~received~~on aJune ~~notice dated February 10~~2, 2009, ~~from~~ the ~~NYSE~~stockholders ~~Amex~~of ~~LLC~~Apex Bioventures Acquisition Corporation (the “~~Exchange~~Company”) ~~stating~~voted ~~that~~to ~~the~~approve the Company’s ispreviously ~~not in~~announced ~~compliance~~dissolution ~~with~~and ~~one~~plan of ~~the requirements for continued listing on the~~ ~~Exchange~~liquidation. ~~Specifically,~~As ~~the~~of ~~Exchange advised that~~ the ~~Company~~close ~~is not in compliance with Section 704~~ of ~~the~~business ~~Exchange’s~~on ~~Company~~June ~~Guide~~2, ~~because~~2009, the Company’s ~~did~~share ~~not~~transfer ~~hold~~books anwill ~~annual~~close ~~meeting~~and ~~during calendar year 2008. The Company was afforded~~ the ~~opportunity~~NYSE toAmex ~~submit~~LLC towill ~~the Exchange a plan of~~suspend ~~compliance and on March 6, 2009 submitted its plan to the Exchange~~trading.

~~On May 8,~~Pursuant ~~2009,~~to the ~~Exchange~~plan ~~notified~~of liquidation, the Company ~~that~~expects itto ~~accepted~~liquidate its trust account, which consists of proceeds from the Company’s ~~plan~~private placement of warrants and ~~compliance~~initial public offering and ~~granted~~the interest accumulated thereon, including the deferred ~~Company~~portion anof ~~extension~~the ~~until~~underwriters’ ~~August~~fee ~~11,~~held ~~2009~~in tothe ~~regain~~trust account following ~~compliance~~consummation ~~with~~of the ~~continued~~public ~~listing standards~~offering. ~~The~~ Liquidating ~~Company~~distributions from ~~will~~the ~~be subject~~trust account are payable upon presentation to ~~periodic~~holders ~~review~~of byshares ~~the~~of common ~~Exchange~~stock ~~staff~~issued ~~during~~in the ~~extension period. Failure~~Company’s toinitial ~~make~~public ~~progress~~offering ~~consistent~~that ~~with~~hold such shares as of the ~~plan~~close orof tobusiness on June 2, 2009. The liquidating distribution ~~regain~~is ~~compliance~~expected ~~with~~to ~~the~~be ~~continued~~approximately ~~listing~~$7.84 ~~standards~~per byshare. ~~the~~No ~~end~~payments will be made with respect to any of the ~~extension~~Company’s ~~period~~outstanding ~~could~~warrants ~~result~~or inshares ~~the~~that ~~Company~~were ~~being~~acquired ~~delisted~~prior ~~from~~to the ~~Exchange~~Company’s initial public offering.

~~On May~~The ~~11,~~Company ~~2009,~~has ~~the~~filed ~~Company~~a ~~issued~~certificate aof ~~press~~dissolution ~~release~~with ~~disclosing~~the ~~its~~Secretary ~~receipt~~of State of the State of Delaware for the ~~above~~purpose of effecting its dissolution and will be ~~summarized~~filing ~~notice~~a Certificate of ~~extension~~Termination ~~from~~of Registration on Form 15 with the Securities and Exchange~~. A~~ ~~copy~~Commission for the purpose of ~~this~~deregistering its ~~press~~securities ~~release~~under isthe ~~attached~~Securities ~~hereto~~and asExchange ~~Exhibit~~Act 99of 1934, as amended.1 As a result, the Company will no longer be a public reporting company and ~~incorporated~~its ~~herein~~securities bywill cease trading on the NYSE Amex ~~reference~~LLC.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

99.1 Press Release, dated ~~May~~June 112, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APEX BIOVENTURES ACQUISITION CORPORATION
	/s/ Darrell J. Elliott
	Darrell J. Elliott
	Chairman and Chief Executive Officer

Dated: ~~May~~June 112, 2009

EXHIBIT INDEX

Exhibit Number	Description	~~Description~~
99.1	Press Release, dated June 2, 2009.	~~Press Release, dated May 11, 2009.~~

Filing Compare · APEX BIOVENTURES ACQUISITION CORP